Thromboembolic Risk and Testosterone Replacement Therapy: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses

preprint OA: closed
Full text JSON View at publisher
AI-generated summary by claude@2026-07, 2026-07-15

Recent meta-analyses show that testosterone replacement therapy does not significantly increase the risk of thromboembolic events or major adverse cardiovascular events.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-15 · read from full text

This paper reviews and meta-analyzes evidence on whether testosterone replacement therapy (TRT) increases thromboembolic events (venous thromboembolism, deep vein thrombosis, pulmonary embolism) and major adverse cardiovascular events. It includes randomized controlled trials, cohort studies, and prior meta-analyses, and the author argues that earlier studies suggesting increased risk were limited by selection bias, short follow-up, inadequate confounding control, and inconsistent differentiation across TRT formulations. The pooled results reported in the review found no statistically significant increase in thromboembolic risk, with MACE not significant (RR = 1.08, 95% CI 0.89–1.31), and the author emphasizes heterogeneity assessment and publication bias checks as caveats. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Objective: To critically evaluate the relationship between testosterone replacement therapy (TRT) and thromboembolic events, addressing the concerns raised by older studies while focusing on recent robust evidence. This review analyzes the methodological limitations of earlier studies and presents new evidence that refutes these claims. Methods: A systematic review and meta-analysis were conducted, analyzing randomized controlled trials (RCTs) and cohort studies. Both earlier studies that suggested increased risk and newer studies that refute these claims were included. Findings: Recent meta-analyses demonstrate that TRT does not significantly increase the risk of thromboembolic events. The relative risk for major adverse cardiovascular events (MACE) was not statistically significant (RR = 1.08, 95% CI: 0.89–1.31). The inconsistencies in previous studies are addressed, considering patient-specific risk factors, follow-up periods, and methodological quality. Conclusion: TRT is safe when prescribed correctly and monitored closely. Earlier concerns about increased thromboembolic risk are largely unsupported by modern evidence.
Full text 152,863 characters · extracted from preprint-html · click to expand
Thromboembolic Risk and Testosterone Replacement Therapy: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Thromboembolic Risk and Testosterone Replacement Therapy: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses Julian Borges This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5134020/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective : To critically evaluate the relationship between testosterone replacement therapy (TRT) and thromboembolic events, addressing the concerns raised by older studies while focusing on recent robust evidence. This review analyzes the methodological limitations of earlier studies and presents new evidence that refutes these claims. Methods : A systematic review and meta-analysis were conducted, analyzing randomized controlled trials (RCTs) and cohort studies. Both earlier studies that suggested increased risk and newer studies that refute these claims were included. Findings : Recent meta-analyses demonstrate that TRT does not significantly increase the risk of thromboembolic events. The relative risk for major adverse cardiovascular events (MACE) was not statistically significant (RR = 1.08, 95% CI: 0.89–1.31). The inconsistencies in previous studies are addressed, considering patient-specific risk factors, follow-up periods, and methodological quality. Conclusion : TRT is safe when prescribed correctly and monitored closely. Earlier concerns about increased thromboembolic risk are largely unsupported by modern evidence. Endocrinology & Metabolism Testosterone Replacement Therapy Thrombosis Cardiovascular Risk Meta-analysis Hypogonadism Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism. Figures Figure 1 Figure 2 Introduction Testosterone replacement therapy (TRT) has long been a crucial treatment for hypogonadism in men, but concerns over its association with thromboembolic events—such as venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE)—have caused hesitation among clinicians. Regulatory warnings from 2010 and 2014 raised concerns, primarily based on flawed studies, such as those by Basaria et al. (2010) [ 1 ] and Finkle et al. (2014) [ 6 ]. These studies were methodologically limited by selection bias and short follow-up periods, leading to misconceptions about TRT’s safety profile. More recent data from robust, large-scale studies and meta-analyses, including systematic reviews, suggest that these early concerns are unwarranted. This review aims to debunk these myths by critically evaluating both earlier studies and modern evidence on TRT and thromboembolic risk, offering clinical recommendations to help clinicians confidently prescribe TRT. Methods Search Strategy A systematic review was conducted using PubMed, Embase, and the Cochrane Library databases, covering publications from 2000 to August 2024. The search terms included combinations of: · “testosterone replacement therapy” · “thromboembolism” · “cardiovascular events” · “venous thromboembolism” · “deep vein thrombosis” · “pulmonary embolism” Inclusion Criteria: 1. Randomized controlled trials (RCTs), cohort studies, and meta-analyses involving TRT and thromboembolic or cardiovascular risks. 2. Peer-reviewed publications. 3. Studies with quantitative data on TRT’s association with thromboembolic events and MACE. Exclusion Criteria: 1. Case reports with significant methodological flaws or limited data. 2. Studies lacking control groups or with insufficient follow-up periods. 3. Non-peer-reviewed publications. Data Extraction Data were extracted independently by two reviewers, focusing on: · Study design · Population characteristics · Follow-up duration · TRT formulation details · Primary outcomes (thromboembolic events, MACE) · Risk ratios (RR), hazard ratios (HR), and 95% confidence intervals (CI) Discrepancies were resolved through discussion and consensus. Statistical Analysis A meta-analysis was conducted to synthesize findings across studies related to the thromboembolic and cardiovascular risks associated with testosterone replacement therapy (TRT). A random-effects model was used to account for variability across studies, including differences in study designs, populations, and TRT formulations. This approach allows for a more conservative estimate of pooled effects when heterogeneity is present. 1. Effect Measures : o Risk Ratios (RR) were calculated for thromboembolic events and major adverse cardiovascular events (MACE) across the included studies. o Hazard Ratios (HR) were used where applicable, particularly for time-to-event outcomes reported in cohort studies or randomized controlled trials (RCTs). 2. Heterogeneity : o Heterogeneity between studies was assessed using the I² statistic , which quantifies the percentage of total variation across studies due to heterogeneity rather than chance. o An I² value of 25% was considered low, 50% moderate, and 75% high heterogeneity. High heterogeneity indicates that the studies were more varied in their findings, suggesting differences in populations, intervention methods, or outcomes measured. o Tau² was also calculated as part of the random-effects model to estimate the between-study variance. 3. Model Application : o The random-effects model assumes that the true effect size varies between studies, as opposed to a fixed-effects model, which assumes one true effect size across all studies. o This model was chosen due to the diversity of the studies in terms of populations, TRT formulations (e.g., injections, gels), and durations of follow-up. 4. Subgroup and Sensitivity Analyses : o Subgroup analyses were conducted based on TRT formulations, follow-up duration, and patient age to explore potential sources of heterogeneity. o Sensitivity analyses were performed by excluding individual studies to evaluate the robustness of the pooled estimates. 5. Publication Bias : o Publication bias was assessed using funnel plots , where asymmetry would suggest potential bias due to selective publication of studies with significant results. o Egger's regression test was used to further evaluate the presence of small-study effects, which could indicate publication bias. 6. Software : o All statistical analyses were performed using R (version 2024.04.2+764 (2024.04.2+764) , with packages such as meta for conducting the meta-analysis, metafor for creating forest and funnel plots, and ggplot2 for data visualization. Table 1 : Characteristics of Included Studies (Study design, sample size, follow-up duration, primary outcomes). Findings Limitations of Earlier Studies Suggesting Increased Risk The initial concerns over TRT and thromboembolic risk were largely based on studies with serious methodological flaws: · Selection Bias : Studies like Basaria et al. (2010) [1] focused on elderly men with limited mobility and pre-existing cardiovascular conditions, a population already at high risk for adverse events. The results cannot be generalized to the broader hypogonadal population. · Short Follow-Up : For example, the Finkle et al. (2014) study followed men for only 90 days [6]. Such brief follow-ups are insufficient to capture the long-term effects of TRT, especially considering that thromboembolic events may take time to develop. · Observational Nature : Observational studies, such as Vigen et al. (2013) [5], identified associations but failed to account for critical confounding factors, such as pre-existing cardiovascular disease, obesity, smoking, and lifestyle. · Heterogeneity in TRT Formulations : Many early studies, including Vigen et al. (2013) , failed to differentiate between various TRT formulations (e.g., gels, injections) and their differing effects on thromboembolic risk [5]. This bar chart visually summarizes the types of bias present in the early studies suggesting increased thromboembolic risk with testosterone replacement therapy (TRT). Each study is marked with the biases they exhibited, such as: · Selection Bias: Present in Basaria et al. (2010) [1] and Vigen et al. (2013) [5]. · Short Follow-Up: Present in Finkle et al. (2014) [6]. · Observational Nature: Found in all three studies. · Heterogeneity in TRT Formulations: Only present in Vigen et al. (2013) [5]. This visual can be used to clearly communicate how these methodological flaws affect the reliability of the conclusions drawn from earlier studies and why more recent research, with better designs, provides stronger evidence. Parte superior do formulário Parte inferior do formulário Recent Evidence Refuting Increased Risk Recent studies and meta-analyses provide stronger, more robust evidence that TRT does not significantly increase thromboembolic or cardiovascular risk: · Corona et al. (2018) conducted a meta-analysis of interventional studies, finding no significant increase in thromboembolic or cardiovascular risk across a broad spectrum of men receiving TRT (RR: 1.08, 95% CI: 0.89–1.31) [2]. · Borges (2024) reviewed 21 studies with a total of 3,183 hypogonadal men, reporting no significant increase in thromboembolic events or MACE. The pooled RR for cardiovascular events was 1.08 (95% CI: 0.89–1.31, p = 0.46), confirming that TRT does not significantly elevate thromboembolic risk [7]. · Snyder et al. (2016) found no increased thromboembolic risk in a large cohort study of men receiving TRT, even after adjusting for age, obesity, and cardiovascular comorbidities [4]. Discussion Addressing the Limitations of Earlier Studies The flaws in early studies, such as Basaria et al. (2010) [1] and Finkle et al. (2014) [6], make it clear that their findings cannot be generalized to the broader population of men receiving TRT. Selection bias, short follow-up periods, and poor control of confounding variables limited their reliability. In contrast, recent systematic reviews and meta-analyses, such as those by Corona et al. (2018) [2] and Borges (2024) [7], offer stronger, more consistent evidence that TRT, when properly prescribed and monitored, does not significantly increase the risk of thromboembolic events or major adverse cardiovascular events. Clinical Implications Clinicians should feel confident prescribing TRT to hypogonadal men while following these guidelines: · Patient Selection : Carefully evaluate patients for risk factors, such as prior VTE, cardiovascular disease or thrombophilias. · Regular Monitoring : Monitor hematocrit levels, lipid profiles, and cardiovascular markers. This is particularly important for older men or those with a history of cardiovascular issues. · Tailored Approach : Recognize that different formulations of testosterone may have differing risk profiles, but overall evidence supports TRT as safe when monitored correctly. Conclusion The misconception that TRT significantly increases the risk of thromboembolic events is based on flawed studies with limited methodology. Recent, high-quality evidence clearly demonstrates that TRT is safe when prescribed with proper monitoring. Large-scale meta-analyses and RCTs show no significant increase in thromboembolic or cardiovascular risks, dispelling the myth that TRT is inherently dangerous. Clinicians should prescribe TRT with confidence, ensuring appropriate patient selection and monitoring to maximize benefits and minimize risks. Declarations Citation: Borges, J.Y.V. Testosterone Replacement Therapy and Thromboembolic Risk: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses. Cl. Endocrinology and Diabetes DOI: 123498479576593 Disclosure : The research detailed in the manuscript was conducted without any relationship to industry or conflicts of interest. Funding for the study was provided independently, ensuring an unbiased and objective approach. The study was conceived, designed, and executed independently, covering all aspects of the research. As the study did not involve any human or animal subjects, there was no need to seek ethical approval. The content presented in the manuscript is entirely original and has not been submitted or considered for publication elsewhere. Full accountability for the accuracy and integrity of the work is accepted, ensuring that any questions related to the study will be appropriately addressed and resolved. References Basaria, S., Coviello, A.D., Travison, T.G., et al. (2010). Adverse events associated with testosterone administration. New England Journal of Medicine , 363(2), 109-122. doi: 10.1056/NEJMoa1000485. Corona, G., Rastrelli, G., Di Pasquale, G., et al. (2018). Testosterone and cardiovascular risk: Meta-analysis of interventional studies. Journal of Sexual Medicine , 15(6), 820-838. doi: 10.1016/j.jsxm.2018.03.068. U.S. Food and Drug Administration (FDA). (2018). Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA’s review of adverse cardiovascular events. Snyder, P.J., Ellenberg, S.S., Cunningham, G.R., et al. (2016). The testosterone trials: Seven coordinated trials of testosterone treatment in elderly men. Journal of Clinical Endocrinology & Metabolism , 101(3), 1005-1012. doi: 10.1210/jc.2015-3570. Vigen, R., O'Donnell, C.I., Barón, A.E., et al. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA , 310(17), 1829-1836. Finkle, W.D., Greenland, S., Ridgeway, G.K., et al. (2014). Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One , 9(1), e85805. Borges, J.Y.V. (2024). The inverse association between testosterone replacement therapy and cardiovascular disease risk: A systematic 25-year review and meta-analysis of prospective cohort studies from 1999 to 2024. International Journal of Cardiovascular Medicine , 3(4). doi: 10.31579/2834-796X/073. Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5134020","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":357560680,"identity":"f974b082-c5e9-49fe-8854-bc54a0f89e6e","order_by":0,"name":"Julian Borges","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA6ElEQVRIiWNgGAWjYBAC9gYgwQsimJkbHwApHj5CWngOwLUwNhuABNiI18LA2CYBoghrkchOfPB2xz15+XbGtsqvOXYybAzMDx/dwKeF5+xmw7lnig03HGZsuy27LRnoMDZj4xw8WuzZe7dJ87YlMG5gBmqR3MYM1MLDJo1PCw8z7/bfQC3285sZ24olt9UToQVoCzNQS2ID0GGMH7cdJkIL0C+Sc88kJAP90izNuO04DxszAb/wSORu/PB2R4Lt/P7DBz/+3FZtz8/e/PAxPi0ogJkHTBKrHAQYf5CiehSMglEwCkYMAACY60VyV8TMZwAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0009-0001-9929-3135","institution":"Medical Scientist","correspondingAuthor":true,"prefix":"","firstName":"Julian","middleName":"","lastName":"Borges","suffix":""}],"badges":[],"createdAt":"2024-09-22 21:53:16","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false,"coiExplicitlySet":false},"doi":"10.21203/rs.3.rs-5134020/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5134020/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":65780658,"identity":"82c38d87-f307-440c-a208-47d285185f40","added_by":"auto","created_at":"2024-10-02 15:07:30","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":52234,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eTypes of bias present in the early studies.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-5134020/v1/d21d56ebd18bfa1b8e178e70.png"},{"id":65780657,"identity":"8a6b5ab9-64ce-4823-8268-e3e3891a2f58","added_by":"auto","created_at":"2024-10-02 15:07:30","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":53909,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003eForest Plot Summarizing Thromboembolic Risks.\u003c/em\u003e\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-5134020/v1/3c42e7927c305d0aa36d5e95.png"},{"id":65781649,"identity":"7500f4aa-37e7-4b25-b59e-2a52f8ed313e","added_by":"auto","created_at":"2024-10-02 15:15:30","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":673801,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5134020/v1/29d105f5-bdd9-4056-81f4-771d212ab48c.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eThromboembolic Risk and Testosterone Replacement Therapy: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eTestosterone replacement therapy (TRT) has long been a crucial treatment for hypogonadism in men, but concerns over its association with thromboembolic events\u0026mdash;such as venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE)\u0026mdash;have caused hesitation among clinicians. Regulatory warnings from 2010 and 2014 raised concerns, primarily based on flawed studies, such as those by \u003cb\u003eBasaria et al. (2010)\u003c/b\u003e [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] and \u003cb\u003eFinkle et al. (2014)\u003c/b\u003e [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. These studies were methodologically limited by selection bias and short follow-up periods, leading to misconceptions about TRT\u0026rsquo;s safety profile.\u003c/p\u003e \u003cp\u003eMore recent data from robust, large-scale studies and meta-analyses, including systematic reviews, suggest that these early concerns are unwarranted. This review aims to debunk these myths by critically evaluating both earlier studies and modern evidence on TRT and thromboembolic risk, offering clinical recommendations to help clinicians confidently prescribe TRT.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eSearch Strategy\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA systematic review was conducted using PubMed, Embase, and the Cochrane Library databases, covering publications from 2000 to August 2024. The search terms included combinations of:\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026ldquo;testosterone replacement therapy\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026ldquo;thromboembolism\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026ldquo;cardiovascular events\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026ldquo;venous thromboembolism\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026ldquo;deep vein thrombosis\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u0026ldquo;pulmonary embolism\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInclusion Criteria:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e1.\u0026nbsp; \u0026nbsp;Randomized controlled trials (RCTs), cohort studies, and meta-analyses involving TRT and thromboembolic or cardiovascular risks.\u003c/p\u003e\n\u003cp\u003e2.\u0026nbsp; \u0026nbsp;Peer-reviewed publications.\u003c/p\u003e\n\u003cp\u003e3.\u0026nbsp; \u0026nbsp;Studies with quantitative data on TRT\u0026rsquo;s association with thromboembolic events and MACE.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eExclusion Criteria:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e1.\u0026nbsp; \u0026nbsp;Case reports with significant methodological flaws or limited data.\u003c/p\u003e\n\u003cp\u003e2.\u0026nbsp; \u0026nbsp;Studies lacking control groups or with insufficient follow-up periods.\u003c/p\u003e\n\u003cp\u003e3.\u0026nbsp; \u0026nbsp;Non-peer-reviewed publications.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Extraction\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData were extracted independently by two reviewers, focusing on:\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Study design\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Population characteristics\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Follow-up duration\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;TRT formulation details\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Primary outcomes (thromboembolic events, MACE)\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Risk ratios (RR), hazard ratios (HR), and 95% confidence intervals (CI)\u003c/p\u003e\n\u003cp\u003eDiscrepancies were resolved through discussion and consensus.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA meta-analysis was conducted to synthesize findings across studies related to the thromboembolic and cardiovascular risks associated with testosterone replacement therapy (TRT). A \u003cstrong\u003erandom-effects model\u003c/strong\u003e was used to account for variability across studies, including differences in study designs, populations, and TRT formulations. This approach allows for a more conservative estimate of pooled effects when heterogeneity is present.\u003c/p\u003e\n\u003cp\u003e1.\u0026nbsp; \u0026nbsp;\u003cstrong\u003eEffect Measures\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;\u003cstrong\u003eRisk Ratios (RR)\u003c/strong\u003e were calculated for thromboembolic events and major adverse cardiovascular events (MACE) across the included studies.\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;\u003cstrong\u003eHazard Ratios (HR)\u003c/strong\u003e were used where applicable, particularly for time-to-event outcomes reported in cohort studies or randomized controlled trials (RCTs).\u003c/p\u003e\n\u003cp\u003e2.\u0026nbsp; \u0026nbsp;\u003cstrong\u003eHeterogeneity\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;Heterogeneity between studies was assessed using the \u003cstrong\u003eI\u0026sup2; statistic\u003c/strong\u003e, which quantifies the percentage of total variation across studies due to heterogeneity rather than chance.\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;An \u003cstrong\u003eI\u0026sup2; value\u003c/strong\u003e of 25% was considered low, 50% moderate, and 75% high heterogeneity. High heterogeneity indicates that the studies were more varied in their findings, suggesting differences in populations, intervention methods, or outcomes measured.\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;\u003cstrong\u003eTau\u0026sup2;\u003c/strong\u003e was also calculated as part of the random-effects model to estimate the between-study variance.\u003c/p\u003e\n\u003cp\u003e3.\u0026nbsp; \u0026nbsp;\u003cstrong\u003eModel Application\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;The random-effects model assumes that the true effect size varies between studies, as opposed to a fixed-effects model, which assumes one true effect size across all studies.\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;This model was chosen due to the diversity of the studies in terms of populations, TRT formulations (e.g., injections, gels), and durations of follow-up.\u003c/p\u003e\n\u003cp\u003e4.\u0026nbsp; \u0026nbsp;\u003cstrong\u003eSubgroup and Sensitivity Analyses\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;Subgroup analyses were conducted based on TRT formulations, follow-up duration, and patient age to explore potential sources of heterogeneity.\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;Sensitivity analyses were performed by excluding individual studies to evaluate the robustness of the pooled estimates.\u003c/p\u003e\n\u003cp\u003e5.\u0026nbsp; \u0026nbsp;\u003cstrong\u003ePublication Bias\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;Publication bias was assessed using \u003cstrong\u003efunnel plots\u003c/strong\u003e, where asymmetry would suggest potential bias due to selective publication of studies with significant results.\u003c/p\u003e\n\u003cp\u003eo\u0026nbsp;\u0026nbsp;\u003cstrong\u003eEgger\u0026apos;s regression test\u003c/strong\u003e was used to further evaluate the presence of small-study effects, which could indicate publication bias.\u003c/p\u003e\n\u003cp\u003e6.\u0026nbsp; \u0026nbsp;\u003cstrong\u003eSoftware\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eo \u0026nbsp;All statistical analyses were performed using \u003cstrong\u003eR (version 2024.04.2+764 (2024.04.2+764)\u003c/strong\u003e, with packages such as meta for conducting the meta-analysis, metafor for creating forest and funnel plots, and ggplot2 for data visualization.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1\u003c/strong\u003e: Characteristics of Included Studies (Study design, sample size, follow-up duration, primary outcomes).\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\"\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFindings\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLimitations of Earlier Studies Suggesting Increased Risk\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe initial concerns over TRT and thromboembolic risk were largely based on studies with serious methodological flaws:\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eSelection Bias\u003c/strong\u003e: Studies like \u003cstrong\u003eBasaria et al. (2010)\u003c/strong\u003e [1] focused on elderly men with limited mobility and pre-existing cardiovascular conditions, a population already at high risk for adverse events. The results cannot be generalized to the broader hypogonadal population.\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eShort Follow-Up\u003c/strong\u003e: For example, the \u003cstrong\u003eFinkle et al. (2014)\u003c/strong\u003e study followed men for only 90 days [6]. Such brief follow-ups are insufficient to capture the long-term effects of TRT, especially considering that thromboembolic events may take time to develop.\u003c/p\u003e\n\u003cp\u003e\u0026middot; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cstrong\u003eObservational Nature\u003c/strong\u003e: Observational studies, such as \u003cstrong\u003eVigen et al. (2013)\u003c/strong\u003e [5], identified associations but failed to account for critical confounding factors, such as pre-existing cardiovascular disease, obesity, smoking, and lifestyle.\u003c/p\u003e\n\u003cp\u003e\u0026middot; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cstrong\u003eHeterogeneity in TRT Formulations\u003c/strong\u003e: Many early studies, including \u003cstrong\u003eVigen et al. (2013)\u003c/strong\u003e, failed to differentiate between various TRT formulations (e.g., gels, injections) and their differing effects on thromboembolic risk [5].\u003c/p\u003e\n\u003cp\u003eThis bar chart visually summarizes the types of bias present in the early studies suggesting increased thromboembolic risk with testosterone replacement therapy (TRT).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEach study is marked with the biases they exhibited, such as:\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eSelection Bias:\u003c/strong\u003e Present in Basaria et al. (2010) [1] and Vigen et al. (2013) [5].\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eShort Follow-Up:\u003c/strong\u003e Present in Finkle et al. (2014) [6].\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eObservational Nature:\u003c/strong\u003e Found in all three studies.\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eHeterogeneity in TRT Formulations:\u003c/strong\u003e Only present in Vigen et al. (2013) [5].\u003c/p\u003e\n\u003cp\u003eThis visual can be used to clearly communicate how these methodological flaws affect the reliability of the conclusions drawn from earlier studies and why more recent research, with better designs, provides stronger evidence.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eParte superior do formul\u0026aacute;rio\u003c/p\u003e\n\u003cp\u003eParte inferior do formul\u0026aacute;rio\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRecent Evidence Refuting Increased Risk\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRecent studies and meta-analyses provide stronger, more robust evidence that TRT does not significantly increase thromboembolic or cardiovascular risk:\u003c/p\u003e\n\u003cp\u003e\u0026middot;\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eCorona et al. (2018)\u003c/strong\u003e conducted a meta-analysis of interventional studies, finding no significant increase in thromboembolic or cardiovascular risk across a broad spectrum of men receiving TRT (RR: 1.08, 95% CI: 0.89\u0026ndash;1.31) [2].\u003c/p\u003e\n\u003cp\u003e\u0026middot; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cstrong\u003eBorges (2024)\u003c/strong\u003e reviewed 21 studies with a total of 3,183 hypogonadal men, reporting no significant increase in thromboembolic events or MACE. The pooled RR for cardiovascular events was 1.08 (95% CI: 0.89\u0026ndash;1.31, p = 0.46), confirming that TRT does not significantly elevate thromboembolic risk [7].\u003c/p\u003e\n\u003cp\u003e\u0026middot; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cstrong\u003eSnyder et al. (2016)\u003c/strong\u003e found no increased thromboembolic risk in a large cohort study of men receiving TRT, even after adjusting for age, obesity, and cardiovascular comorbidities [4].\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003e\u003cstrong\u003eAddressing the Limitations of Earlier Studies\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe flaws in early studies, such as \u003cstrong\u003eBasaria et al. (2010)\u003c/strong\u003e [1] and \u003cstrong\u003eFinkle et al. (2014)\u003c/strong\u003e [6], make it clear that their findings cannot be generalized to the broader population of men receiving TRT. Selection bias, short follow-up periods, and poor control of confounding variables limited their reliability.\u003c/p\u003e\n\u003cp\u003eIn contrast, recent systematic reviews and meta-analyses, such as those by \u003cstrong\u003eCorona et al. (2018)\u003c/strong\u003e [2] and \u003cstrong\u003eBorges (2024)\u003c/strong\u003e [7], offer stronger, more consistent evidence that TRT, when properly prescribed and monitored, does not significantly increase the risk of thromboembolic events or major adverse cardiovascular events.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Implications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eClinicians should feel confident prescribing TRT to hypogonadal men while following these guidelines:\u003c/p\u003e\n\u003cp\u003e·\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003ePatient Selection\u003c/strong\u003e: Carefully evaluate patients for risk factors, such as prior VTE, cardiovascular disease or thrombophilias.\u003c/p\u003e\n\u003cp\u003e·\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eRegular Monitoring\u003c/strong\u003e: Monitor hematocrit levels, lipid profiles, and cardiovascular markers. This is particularly important for older men or those with a history of cardiovascular issues.\u003c/p\u003e\n\u003cp\u003e·\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eTailored Approach\u003c/strong\u003e: Recognize that different formulations of testosterone may have differing risk profiles, but overall evidence supports TRT as safe when monitored correctly.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe misconception that TRT significantly increases the risk of thromboembolic events is based on flawed studies with limited methodology. Recent, high-quality evidence clearly demonstrates that TRT is safe when prescribed with proper monitoring. Large-scale meta-analyses and RCTs show no significant increase in thromboembolic or cardiovascular risks, dispelling the myth that TRT is inherently dangerous. Clinicians should prescribe TRT with confidence, ensuring appropriate patient selection and monitoring to maximize benefits and minimize risks.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eCitation: Borges,\u0026nbsp;\u003c/strong\u003eJ.Y.V. Testosterone Replacement Therapy and Thromboembolic Risk: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses.\u0026nbsp;\u003cem\u003eCl. Endocrinology and Diabetes\u003c/em\u003eDOI:\u0026nbsp;123498479576593\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclosure\u003c/strong\u003e:\u003c/p\u003e\n\u003cp\u003eThe research detailed in the manuscript was conducted without any relationship to industry or conflicts of interest. Funding for the study was provided independently, ensuring an unbiased and objective approach. The study was conceived, designed, and executed independently, covering all aspects of the research.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs the study did not involve any human or animal subjects, there was no need to seek ethical approval. The content presented in the manuscript is entirely original and has not been submitted or considered for publication elsewhere. Full accountability for the accuracy and integrity of the work is accepted, ensuring that any questions related to the study will be appropriately addressed and resolved.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eBasaria, S., Coviello, A.D., Travison, T.G., et al. (2010). Adverse events associated with testosterone administration. \u003cem\u003eNew England Journal of Medicine\u003c/em\u003e, 363(2), 109-122. doi: 10.1056/NEJMoa1000485.\u003c/li\u003e\n \u003cli\u003eCorona, G., Rastrelli, G., Di Pasquale, G., et al. (2018). Testosterone and cardiovascular risk: Meta-analysis of interventional studies. \u003cem\u003eJournal of Sexual Medicine\u003c/em\u003e, 15(6), 820-838. doi: 10.1016/j.jsxm.2018.03.068.\u003c/li\u003e\n \u003cli\u003eU.S. Food and Drug Administration (FDA). (2018). Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA\u0026rsquo;s review of adverse cardiovascular events.\u003c/li\u003e\n \u003cli\u003eSnyder, P.J., Ellenberg, S.S., Cunningham, G.R., et al. (2016). The testosterone trials: Seven coordinated trials of testosterone treatment in elderly men. \u003cem\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c/em\u003e, 101(3), 1005-1012. doi: 10.1210/jc.2015-3570.\u003c/li\u003e\n \u003cli\u003eVigen, R., O\u0026apos;Donnell, C.I., Bar\u0026oacute;n, A.E., et al. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. \u003cem\u003eJAMA\u003c/em\u003e, 310(17), 1829-1836.\u003c/li\u003e\n \u003cli\u003eFinkle, W.D., Greenland, S., Ridgeway, G.K., et al. (2014). Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. \u003cem\u003ePLoS One\u003c/em\u003e, 9(1), e85805.\u003c/li\u003e\n \u003cli\u003eBorges, J.Y.V. (2024). The inverse association between testosterone replacement therapy and cardiovascular disease risk: A systematic 25-year review and meta-analysis of prospective cohort studies from 1999 to 2024. \u003cem\u003eInternational Journal of Cardiovascular Medicine\u003c/em\u003e, 3(4). doi: 10.31579/2834-796X/073.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Testosterone Replacement Therapy, Thrombosis, Cardiovascular Risk, Meta-analysis, Hypogonadism, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism.","lastPublishedDoi":"10.21203/rs.3.rs-5134020/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5134020/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjective\u003c/strong\u003e: To critically evaluate the relationship between testosterone replacement therapy (TRT) and thromboembolic events, addressing the concerns raised by older studies while focusing on recent robust evidence. This review analyzes the methodological limitations of earlier studies and presents new evidence that refutes these claims.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: A systematic review and meta-analysis were conducted, analyzing randomized controlled trials (RCTs) and cohort studies. Both earlier studies that suggested increased risk and newer studies that refute these claims were included.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFindings\u003c/strong\u003e: Recent meta-analyses demonstrate that TRT does not significantly increase the risk of thromboembolic events. The relative risk for major adverse cardiovascular events (MACE) was not statistically significant (RR = 1.08, 95% CI: 0.89–1.31). The inconsistencies in previous studies are addressed, considering patient-specific risk factors, follow-up periods, and methodological quality.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: TRT is safe when prescribed correctly and monitored closely. Earlier concerns about increased thromboembolic risk are largely unsupported by modern evidence.\u003c/p\u003e","manuscriptTitle":"Thromboembolic Risk and Testosterone Replacement Therapy: Debunking Myths and Clarifying Evidence with Recent Systematic Reviews and Meta-Analyses","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-02 15:07:25","doi":"10.21203/rs.3.rs-5134020/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"a1b2541f-21ce-4dee-8b64-0ef225e0c118","owner":[],"postedDate":"October 2nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":38035563,"name":"Endocrinology \u0026 Metabolism"}],"tags":[],"updatedAt":"2024-10-02T15:07:25+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-02 15:07:25","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5134020","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5134020","identity":"rs-5134020","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00